NCT02960555View on ClinicalTrials.gov

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2030

Conditions
Smoldering Plasma Cell Myeloma
Interventions
BIOLOGICAL

Isatuximab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (3)

10029

Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER